BioSpace - Print News Article

Teva Pharmaceutical Industries Limited (TEVA) and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint 9/7/2011 10:51:20 AM JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD). Results showed MG01CI met the primary efficacy outcome, demonstrating a significant improvement on the Conners’ Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms Score (CAARS-INV) compared to placebo (p<0.03).

Teva Pharmaceutical Industries Limited (TEVA) and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint
9/7/2011 10:51:20 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD). Results showed MG01CI met the primary efficacy outcome, demonstrating a significant improvement on the Conners’ Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms Score (CAARS-INV) compared to placebo (p<0.03).